Josiah Joseph  Isah

Dr. Josiah Joseph Isah

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2025 in In Silico Research in Biomedicine
Verified
Journal Article
Open access
JIJosiah Joseph Isah
Josiah Joseph Isah
AUAdamu Uzairu
Adamu Uzairu
SUSani Uba
Sani Uba
MIMuhammad Tukur Ibrahim
Muhammad Tukur Ibrahim

1 October 2025 in Letters in Drug Design & Discovery
Verified
Journal Article
Open access
JIJosiah Joseph Isah
Josiah Joseph Isah
AUAdamu Uzairu
Adamu Uzairu
SUSani Uba
Sani Uba
MIMuhammad Tukur Ibrahim
Muhammad Tukur Ibrahim


2 September 2025 in In Silico Research in Biomedicine
Verified
Journal Article
Open access
JIJosiah Joseph Isah
Josiah Joseph Isah
AUAdamu Uzairu
Adamu Uzairu
SUSani Uba
Sani Uba
MIMuhammad Tukur Ibrahim
Muhammad Tukur Ibrahim

11 December 2025 in Discover Chemistry
Verified
Journal Article
Open access
PDF file
JIJosiah Joseph Isah
Josiah Joseph Isah
AUAdamu Uzairu
Adamu Uzairu
SUSani Uba
Sani Uba
MIMuhammad Tukur Ibrahim
Muhammad Tukur Ibrahim
Interleukin-1 receptor-associated kinase 4 (IRAK4) is a key mediator of MYD88^L265P-driven diffuse large B-cell lymphoma (DLBCL) and a promising drug target. We applied an integrated in silico pipeline, namely, 2D-QSAR (MLR with GA), molecular docking, ADMET profiling, and 100-ns molecular dynamics, to prioritize pyrrolopyrimidine-based IRAK4 inhibitors. The final 2D-QSAR model achieved R² = 0.7279, Q²_LOO = 0.5982, and CCC = 0.7748 and showed good external predictability (RMSE_test = 0.4441, CCC_test = 0.6934). Docking identified compound 15 (− 10.1 kcal·mol⁻¹) and its optimized analogue 15c (− 10.3 kcal·mol⁻¹) as the top binders. Compound 15c exhibited strong binding (MM-GBSA ΔG_bind = − 66.41 kcal·mol⁻¹ vs. − 57.86 kcal·mol⁻¹ for ND-2158), high predicted intestinal absorption (~ 91.6%), and AMES-negative status; 100-ns MD confirmed a stable binding pose. While experimental validation is needed, compound 15c is prioritized as a promising lead for MYD88-mutant DLBCL. Graphical abstract

26 November 2025 in In Silico Pharmacology
Verified
Journal Article
Closed access
PDF file
JIJosiah Joseph Isah
Josiah Joseph Isah
AUAdamu Uzairu
Adamu Uzairu
SUSani Uba
Sani Uba
MIMuhammad Tukur Ibrahim
Muhammad Tukur Ibrahim